OKYO Pharma Limited (" OKYO ", " OKYO Pharma " or the " Company ") OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023. London and New York, NY

("OKYO", "OKYO Pharma" or the "Company")

OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug

Discovery Summit in Boston, MA on February 21-23, 2023.

London and New York, NY, February 21, 2023

- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101

to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, today announced that its CEO, Gary

S. Jacob, Ph.D., will be giving an oral presentation entitled: "A Lipidated Protease-Resistant Chemerin Peptide Offers a Novel Therapeutic

for Dry Eyes" on February 22, 2023 at the 2nd Annual GPCRs-Targeted Drug Discovery Summit at the Hyatt Regency in Boston,

MA. Dr. Jacob's talk, which is scheduled for the afternoon of February 22, will cover the planned clinical development of OKYO's

drug candidate OK-101 to treat dry eye disease (DED).

Dr. Jacob's presentation will be preceded

by an oral presentation carrying the same presentation title as Dr. Jacob's talk which will be given by Dr. Alan Kopin, Chief Scientific

Officer of On Target Therapeutics, and the inventor of OK-101, who will be presenting the research work that led to the discovery of OK-101

as well as in vivo testing and animal model studies conducted with OK-101. Dr. Jacob will follow with the progress that has led

to the recent filing of an Investigational New Drug (IND) application with FDA on OK-101 to treat DED, and the Company's plans to

open a phase 2 trial of OK-101 in patients with DED in the first quarter of 2023.

On December 22, 2022, OKYO announced that it had

received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase

2, first-in-human, clinical study of OK-101 for the treatment of DED.

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO)

is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct

Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and

development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For further information, please visit www.okyopharma.com.

OK-101 is a lipid conjugated chemerin peptide

antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory

response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce a novel long-acting drug candidate for treating

dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and

corneal neuropathic pain; and is designed to combat washout through the inclusion of the lipid anchor' contained in the candidate

drug molecule to enhance the residence time of OK-101 within the ocular environment.

Forward-Looking Statements

Certain statements made in this announcement are

forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations,

estimates, and projections about its industry; its beliefs; and assumptions. Words such as anticipates,' expects,' intends,' plans,'

believes,' 'seeks,' estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not

guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond

the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted

in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance

on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking

statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake

any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated

events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further information, please visit the Company's

website at www.okyopharma.com

The person who arranged for the release of this

announcement on behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO.